Showing results (1871-1880 of 1,881) with videos related to
Sort By:
Pageof 189
Immunotherapy|June 19, 2026
Recent advances in bispecific natural killer cell engagers for cancer immunotherapyMousa Thalji, Yago NietoImmunotherapy|June 29, 2026
Anti-TIGIT therapies in digestive cancers: from immune evasion to precision immunotherapyMarianne Matar, Céline Yaghi, Gilles Prince, et al.Immunotherapy|July 28, 2026
Green synthesis nanoparticles for cancer immunotherapy: current applications and future perspectivesZahraa AlKhafaje, H Malathi, Aniruddh Dash, et al.Immunotherapy|August 10, 2026
Cost-effectiveness analysis of Nivolumab plus Ipilimumab versus Nivolumab monotherapy in previously treated metastatic colorectal cancer patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) in ChinaXiaohong Zhu, Xu Yang, Tong LiuImmunotherapy|August 25, 2026
Low-dose interleukin-2 combined with thalidomide for a severe cutaneous immune-related adverse event associated with PD-1/CTLA-4 bispecific antibody therapy: a case reportZhiqiang Li, Yufei Li, Yuhan Zhang, et al.Immunotherapy|August 25, 2026
Efficacy of PARP inhibitor and immune checkpoint inhibitor combination therapy in PD-L1-negative cancers: a systematic review and meta-analysisSusu Zhou, Vishw Patel, Noriko Kishi, et al.Immunotherapy|August 24, 2026
Injection-based safety of aqueous venom immunotherapy during venom extract shortage: impact of forced depot-to-aqueous switchingGökten Bulut, Rukiye Demiralp, Şefika Karabaş, et al.Immunotherapy|September 5, 2026
Cancer vaccines as targeted therapies: translational advances and challengesZahra Shafaghat, Maryam Sadri, Mona Roozbehani, et al.Immunotherapy|September 7, 2026
Bromodomain inhibitors in autoimmune diseasesMarcin Szczepanik, Wojciech Pociej, Joanna Kulpa, et al.Immunotherapy|September 2, 2026
Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinomaCaner Kapar, Oğuzcan Özkan, Eda Eylemer Mocan, et al.Pageof 189